Azurion 5 M20
Payments companies reported to CMS as associated with Azurion 5 M20. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Azurion 5 M20, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Azurion 5 M20
These are the largest totals companies reported as associated with Azurion 5 M20. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Sarang Mangalmurti | Bryn Mawr, PA | Cardiovascular Disease | $1,198.32 |
| Aaron Losey | Albuquerque, NM | Diagnostic Radiology | $1,027.57 |
| Michael Gen | Virginia Beach, VA | Interventional Cardiology | $313.72 |
| Dana Mann | Bend, OR | Diagnostic Radiology | $160.24 |
| Vinit Lal | North Richland Hills, TX | Interventional Cardiology | $98.82 |
| Joji Varghese | Abilene, TX | Interventional Cardiology | $98.81 |
| Arsalan Shahzad | Tomball, TX | Cardiovascular Disease | $89.40 |
| Arif Shahzad | The Woodlands, TX | Rheumatology | $89.40 |
| Reehan Shahzad | Tomball, TX | Cardiovascular Disease | $89.40 |
| Atif Shahzad | The Woodlands, TX | Gastroenterology (Internal Medicine) | $89.40 |
Prescribed Azurion 5 M20?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.